Yes, looks that way.
One would assume their future forecast customer orders of $7m by end of CY2017 could balloon.
Add the Nanatron forecast of US$4.2m revenue in CY17 and it's looking very good here.
The successfully transition of an anchor customer to manufacturing phase will be a big catalyst IMO.
And obviously massive upside will play out if they aggressively build their pipeline.
Ann: Expansion of facility in advance of commercial Medtech order, page-9
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
